Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma

http://www.wikidata.org/entity/Q33924781

about

DNA vaccine for cancer immunotherapy Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma Preclinical and clinical development of DNA vaccines for prostate cancer.CSPG4: a prototype oncoantigen for translational immunotherapy studies.Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Strategies for cancer vaccine development.Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.Immunotherapy for melanoma: current status and perspectives.Harnessing DNA-induced immune responses for improving cancer vaccines.Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults.Trial watch: DNA vaccines for cancer therapy.CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases State of the art in tumor antigen and biomarker discovery.Emerging cancer vaccines: the promise of genetic vectors.Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma.The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy.DNA vaccination: using the patient's immune system to overcome cancer Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.Melanoma treatment in review.

P2860

Q28080919-DB66639D-489A-4403-9940-D50B6654B008 Q33606137-4ED8D755-90C0-4971-9D1B-8A18E14ED840 Q33740811-A4403B1B-BE22-49AD-A19E-68C6FB13CC11 Q33862585-6F8F16E4-1EBA-4635-9622-808685A49622 Q33907628-3FB889AE-5EFB-4EE7-93B9-25DDBCB6B176 Q34000700-4D922D3E-401A-4A65-A1AF-A43E1FE49371 Q34038338-B3EB7605-F7B8-4C39-A876-64B6D8383677 Q34173622-118406A7-3EA9-4C6F-9114-1D58DDF56B7B Q34522301-AB6DC3F6-7CF0-447A-932B-DA61AEF5FBBD Q34561877-465B26C3-8DBD-42A3-8674-8C103795AB8B Q35289145-68BEE9DE-FE50-4DBA-9B6C-A16B5AC8700C Q35600772-DCAD1AC8-A221-4E2C-8454-3481CA97D160 Q36453216-945DF6A9-EF06-47BF-A6C9-CF8B233BB99B Q36694866-CE97D3F7-7B39-465A-ACA7-68E27FCE9083 Q36765132-C6E3727D-5200-4FEC-A0D6-07B096F36DE1 Q36845824-84F9E8F2-F38C-4651-AC69-BC26525F37B5 Q36846646-510C1759-C92E-49F3-A410-36F5E767AC1E Q37132800-4FBE25B1-3F57-4B23-A7E3-A274CA3CF715 Q37137464-FDC532E9-77E3-4BD0-ADE6-02DE3F8B0728 Q37703163-CC2B1993-3B90-4DFE-A86F-8B5B8300D246 Q37727531-3902D413-FE4B-41BC-9FF2-0497D7DEC9E7 Q37729321-E4189A5B-4601-4A64-9A01-B13001D7E067 Q37825422-9816F237-8D4A-4720-980A-EDECC27AADA0 Q41679793-A0B7BB82-FD2E-4EB2-96AE-AAED947B867F Q55217220-1C5773C5-3E8D-449B-830B-E3D328243447

P2860

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma

http://www.wikidata.org/entity/Q33924781

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety and immunogenicity of a ...... rial of patients with melanoma

@ast

Safety and immunogenicity of a ...... rial of patients with melanoma

@en

type

label

Safety and immunogenicity of a ...... rial of patients with melanoma

@ast

Safety and immunogenicity of a ...... rial of patients with melanoma

@en

prefLabel

Safety and immunogenicity of a ...... rial of patients with melanoma

@ast

Safety and immunogenicity of a ...... rial of patients with melanoma

@en

P1433

Q33924781-B6502AFC-FA4C-429F-893D-E61DB7CC6E18

P1476

Q33924781-241CD082-9657-4E99-9A62-2E26903A4183

P2093

Q33924781-0BB849C0-D000-4B37-9D56-25834897BFA0

Q33924781-13BC79BB-B780-47BC-869E-2C0C0CC3344E

Q33924781-31FA55FA-35EA-49FC-84B9-7CCA196B5746

Q33924781-429869BE-4238-46DA-9341-DFDD0B18CCB1

Q33924781-43A4B5EF-E348-486E-A462-470DB9F82670

Q33924781-54BD8F54-5BE0-49C7-BD24-F4CE194F2E26

Q33924781-5E1951BC-E385-4A69-B063-FA036BA35C3A

Q33924781-6A1FB2BE-28BC-49DE-99D2-CB44975380F6

Q33924781-8CDD817A-3060-40DD-B08C-9796FC3E9964

Q33924781-A0417A67-39F9-4587-92D3-74796C52D2D1

P2860

Q33924781-038FC811-39CA-43B4-B186-EB62CB660358

Q33924781-14B4C8FF-AEBE-48E5-B31E-C9715A74DCE4

Q33924781-157D7053-BBA1-4B09-914D-E431CA5091BB

Q33924781-2A0B021C-F570-4107-9890-89F0E93305FC

Q33924781-2B5E2430-9FCC-4CBD-A0A2-4CCDA6A1CFE2

Q33924781-2C8CEC7B-D0FA-4E2F-89EF-F23791FA67DB

Q33924781-2F729FAD-7DD3-49E0-B801-65327B32D863

Q33924781-36163DE3-5A6E-4462-BCCE-ADD0126252F0

Q33924781-4D4CB11C-BBA7-4937-BBC5-CEC68A0FD163

Q33924781-4E2B2DB0-A72D-4FE0-98A7-143343B7BF59

P304

Q33924781-30E00556-C2B9-4482-867A-DBBA3837F5DA

P31

Q33924781-E818AAE7-D5C6-4F4A-A3ED-4FE48D39E46F

P478

Q33924781-B5BC40CE-EF15-47A7-AB6A-D1B59C3C679B

P50

Q33924781-B9A81BCE-0E0B-4601-8362-548066BB1557

P577

Q33924781-AF94F9F1-80C6-4836-99BD-268225151DE8

P698

Q33924781-F21AF2F7-80A1-4F1D-89F9-B00B54CB10F5

P921

Q33924781-2F79C167-8B55-4D17-B279-0C2C0AA796AC

P932

Q33924781-F96F57F6-D0E7-4483-9C53-7514CA55B7B8

P1433

Cancer Immunity

P1476

Safety and immunogenicity of a ...... rial of patients with melanoma

@en

P2093

Alan N Houghton

http://www.w3.org/2001/XMLSchema#string

Francesca Orlandi

http://www.w3.org/2001/XMLSchema#string

Gregor Manukian

http://www.w3.org/2001/XMLSchema#string

Hao Li

http://www.w3.org/2001/XMLSchema#string

Humilidad F Gallardo

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Jianda Yuan

http://www.w3.org/2001/XMLSchema#string

Katherine Panageas

http://www.w3.org/2001/XMLSchema#string

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Paul B Chapman

http://www.w3.org/2001/XMLSchema#string

P2860

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma

Cancer statistics, 2008

Central memory and effector memory T cell subsets: function, generation, and maintenance

Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19496531

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2888533

http://www.w3.org/2001/XMLSchema#string